301 related articles for article (PubMed ID: 20536416)
1. Macrocyclic histone deacetylase inhibitors.
Mwakwari SC; Patil V; Guerrant W; Oyelere AK
Curr Top Med Chem; 2010; 10(14):1423-40. PubMed ID: 20536416
[TBL] [Abstract][Full Text] [Related]
2. Recent progress in the development of histone deacetylase inhibitors as anti-cancer agents.
Zhang L; Lei J; Shan Y; Yang H; Song M; Ma Y
Mini Rev Med Chem; 2013 Dec; 13(14):1999-2013. PubMed ID: 24160707
[TBL] [Abstract][Full Text] [Related]
3. Non-peptide macrocyclic histone deacetylase inhibitors.
Oyelere AK; Chen PC; Guerrant W; Mwakwari SC; Hood R; Zhang Y; Fan Y
J Med Chem; 2009 Jan; 52(2):456-68. PubMed ID: 19093884
[TBL] [Abstract][Full Text] [Related]
4. Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton.
Mwakwari SC; Guerrant W; Patil V; Khan SI; Tekwani BL; Gurard-Levin ZA; Mrksich M; Oyelere AK
J Med Chem; 2010 Aug; 53(16):6100-11. PubMed ID: 20669972
[TBL] [Abstract][Full Text] [Related]
5. Natural and Synthetic Macrocyclic Inhibitors of the Histone Deacetylase Enzymes.
Maolanon AR; Kristensen HM; Leman LJ; Ghadiri MR; Olsen CA
Chembiochem; 2017 Jan; 18(1):5-49. PubMed ID: 27748555
[TBL] [Abstract][Full Text] [Related]
6. Structure of 'linkerless' hydroxamic acid inhibitor-HDAC8 complex confirms the formation of an isoform-specific subpocket.
Tabackman AA; Frankson R; Marsan ES; Perry K; Cole KE
J Struct Biol; 2016 Sep; 195(3):373-378. PubMed ID: 27374062
[TBL] [Abstract][Full Text] [Related]
7. Differential protein acetylation induced by novel histone deacetylase inhibitors.
Glaser KB; Li J; Pease LJ; Staver MJ; Marcotte PA; Guo J; Frey RR; Garland RB; Heyman HR; Wada CK; Vasudevan A; Michaelides MR; Davidsen SK; Curtin ML
Biochem Biophys Res Commun; 2004 Dec; 325(3):683-90. PubMed ID: 15541343
[TBL] [Abstract][Full Text] [Related]
8. Why Hydroxamates May Not Be the Best Histone Deacetylase Inhibitors--What Some May Have Forgotten or Would Rather Forget?
Shen S; Kozikowski AP
ChemMedChem; 2016 Jan; 11(1):15-21. PubMed ID: 26603496
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors and cell death.
Zhang J; Zhong Q
Cell Mol Life Sci; 2014 Oct; 71(20):3885-901. PubMed ID: 24898083
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.
Dejligbjerg M; Grauslund M; Litman T; Collins L; Qian X; Jeffers M; Lichenstein H; Jensen PB; Sehested M
Mol Cancer; 2008 Sep; 7():70. PubMed ID: 18789133
[TBL] [Abstract][Full Text] [Related]
11. Peptide based macrocycles: selective histone deacetylase inhibitors with antiproliferative activity.
Rajak H; Singh A; Dewangan PK; Patel V; Jain DK; Tiwari SK; Veerasamy R; Sharma PC
Curr Med Chem; 2013; 20(14):1887-903. PubMed ID: 23409715
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitors in the treatment of hematological malignancies.
Petrella A; Fontanella B; Carratù A; Bizzarro V; Rodriquez M; Parente L
Mini Rev Med Chem; 2011 Jun; 11(6):519-27. PubMed ID: 21561404
[TBL] [Abstract][Full Text] [Related]
13. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
Negmeldin AT; Pflum MKH
Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
[TBL] [Abstract][Full Text] [Related]
14. A structure-activity relationship of non-peptide macrocyclic histone deacetylase inhibitors and their anti-proliferative and anti-inflammatory activities.
Tapadar S; Fathi S; Raji I; Omesiete W; Kornacki JR; Mwakwari SC; Miyata M; Mitsutake K; Li JD; Mrksich M; Oyelere AK
Bioorg Med Chem; 2015 Dec; 23(24):7543-64. PubMed ID: 26585275
[TBL] [Abstract][Full Text] [Related]
15. [Structure-activity relationships of histone deacetylase inhibitors].
Tan YM; Huang WY; Yu NF
Yao Xue Xue Bao; 2009 Oct; 44(10):1072-83. PubMed ID: 20055127
[TBL] [Abstract][Full Text] [Related]
16. Antibody drug conjugates with hydroxamic acid cargos for histone deacetylase (HDAC) inhibition.
Cianferotti C; Faltoni V; Cini E; Ermini E; Migliorini F; Petricci E; Taddei M; Salvini L; Battistuzzi G; Milazzo FM; Anastasi AM; Chiapparino C; De Santis R; Giannini G
Chem Commun (Camb); 2021 Jan; 57(7):867-870. PubMed ID: 33433550
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and Investigation of Therapeutic Potential of Isoform-Specific HDAC8 Inhibitors for the Treatment of Cutaneous T Cell Lymphoma.
Umamaheswari A; Puratchikody A; Hari N
Anticancer Agents Med Chem; 2019; 19(7):916-934. PubMed ID: 30836926
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of histone deacetylase as antitumor agents: A critical review.
Manal M; Chandrasekar MJ; Gomathi Priya J; Nanjan MJ
Bioorg Chem; 2016 Aug; 67():18-42. PubMed ID: 27239721
[TBL] [Abstract][Full Text] [Related]
19. Hydroxamic Acids Immobilized on Resins (HAIRs): Synthesis of Dual-Targeting HDAC Inhibitors and HDAC Degraders (PROTACs).
Sinatra L; Bandolik JJ; Roatsch M; Sönnichsen M; Schoeder CT; Hamacher A; Schöler A; Borkhardt A; Meiler J; Bhatia S; Kassack MU; Hansen FK
Angew Chem Int Ed Engl; 2020 Dec; 59(50):22494-22499. PubMed ID: 32780485
[TBL] [Abstract][Full Text] [Related]
20. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.
Bieliauskas AV; Weerasinghe SV; Negmeldin AT; Pflum MK
Arch Pharm (Weinheim); 2016 May; 349(5):373-82. PubMed ID: 27062198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
